Companies: 10,795·Total market cap: $144.5T
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMSNASDAQHealthcare● Active
$31.06
$-0.46(-1.46%)
Market Cap$3.6B
P/E Ratio—
52W High$42.205
52W Low$17.63
Overview

NewAmsterdam Pharma Company N.V. (NAMS) Number of Employees – History & Annual Headcount

Annual SEC headcount, year-over-year change, and per-employee efficiency — chart and full history below.

SEC EDGAR · FMP · NAMS · as of Feb 18, 2026

Latest filing snapshot

100
+32+47.06%vs prior year

NewAmsterdam Pharma Company N.V. (NAMS) employee data is sourced from the annual SEC 10-K filing. As of 2025, full-time employees only. Global consolidated headcount. View SEC filing ↗

SEC 10-K·Period end: 2025-12-31·Full-time · Global
Total Employees
100
Change (1Y)
+32
Growth % (1Y)
+47.06%
Revenue / Employee
$225.0K
Net Income / Employee
$-2.04M
Market Cap
$3.6B

NAMS Employee Count

2022 – 2025 · Annual · SEC filing

Source: SEC annual filings · Hover bar to view year data · Click to view original filing

Employees History

Filing DateEmployeesChange (1Y)Growth (1Y)SEC filing link
2026-02-18100+32+47.06%
2025-02-2668+39+134.48%
2024-02-2829+12+70.59%
2023-03-3117+17—
2022-11-280——

▸ Source: SEC Annual Reports (Form 10-K / 20-F). Employee counts as of fiscal year end. Click the ↗ icon at the end of a row to open the original SEC filing in a new tab.

Related Companies — Employee Count

Biotechnology
#SymbolCompanyEmployees
#1
Crinetics Pharmaceuticals, Inc.
CRNX
Crinetics Pharmaceuticals, Inc.
437#2
Immunovant, Inc.
IMVT
Immunovant, Inc.
362#3
Kymera Therapeutics, Inc.
KYMR
Kymera Therapeutics, Inc.
208#4
Arcellx, Inc.
ACLX
Arcellx, Inc.
163#5
CG Oncology, Inc. Common stock
CGON
CG Oncology, Inc. Common stock
113#6
NewAmsterdam Pharma Company N.V.
NAMS
NewAmsterdam Pharma Company N.V.YOU
100#7
Akero Therapeutics, Inc.
AKRO
Akero Therapeutics, Inc.
69
Source: /stock-peers + /profile.fullTimeEmployees · Click row → /employees · Sorted by headcount · NAMS peer comparison

About NAMS employees

NAMS Employees · Headcount

NewAmsterdam Pharma Company N.V. (NAMS) employee data is sourced from the annual SEC 10-K filing. As of 2025, NewAmsterdam Pharma Company N.V. had 100 full-time employees globally. Full-time employees only. Global consolidated headcount.

NewAmsterdam Pharma Company N.V. employs 100 full-time employees as of the latest filing within the Biotechnology industry. Revenue per employee stands at $225,030, reflecting the company's operational efficiency.

NewAmsterdam Pharma Company N.V.'s workforce increased by 32 (47.06%) in 2025 compared to the prior fiscal year. The historical trend reflects the company's expansion and contraction cycles.

NewAmsterdam Pharma Company N.V.'s revenue per employee of $225,030 positions it among the notable performers in the Biotechnology sector for operational efficiency.

RevenueFinancial statementsNet incomeSEC filingsPrice historyForecast & ratingsOwnershipEarnings

Frequently Asked Questions

NAMS Employees · 5 questions

As of the latest SEC 10-K filing (2025), NewAmsterdam Pharma Company N.V. had 100 full-time employees globally. This figure is sourced from the company's mandatory annual disclosure to the SEC.

NewAmsterdam Pharma Company N.V. employee counthow many employees does NewAmsterdam Pharma Company N.V. haveNAMS total employees 2025

▸ Data source: FMP /historical-employee-count · SEC EDGAR annual filings · As reported · Global consolidated headcount · As of 2026-02-18